GlassScriptPhysician profile
Andrew See
NPI 1477902682
$22,902.99
in general payments reported to CMS, 2019-2025
22 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $206 · 2024: $685 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $5,924 · Food and Beverage: $3,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,350.00 |
| Travel and Lodging | $5,924.49 |
| Food and Beverage | $3,628.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20,790.03 | 2024-2025 | Yeztugo, Descovy |
| Viiv Healthcare Company | $584.12 | 2024-2025 | Apretude |
| Novo Nordisk INC | $264.77 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $151.56 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Ardelyx, INC. | $141.13 | 2024-2025 | Ibsrela |
| Amgen INC. | $124.34 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $113.22 | 2023-2025 | Ubrelvy, Qulipta |
| Exact Sciences Corporation | $110.52 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $82.89 | 2024-2025 | |
| Axsome Therapeutics, INC. | $80.28 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $67.05 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lundbeck LLC | $58.87 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $53.57 | 2025 | |
| Dexcom, INC. | $46.43 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $43.61 | 2023-2025 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37.87 | 2025 | Bexsero, Shingrix, Arexvy |
| Vertex Pharmaceuticals Incorporated | $30.81 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $29.87 | 2023 | Seglentis |
| Abbott Laboratories | $26.30 | 2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.28 | 2023 | Jardiance |
| Hologic Sales and Service, LLC | $21.56 | 2025 | Aptima |
| Dynavax Technologies Corporation | $19.91 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew See listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.